New American Edge Project Poll Highlights Unity Against Foreign Technological Threats

American Edge Project (AEP) recently released a new survey of U.S. and European voters in order to gauge their thoughts on Chinese and Russian technological threats. The poll surveyed 1,001 registered voters in the U.S., 1,000 registered voters in the U.K., 1,001 registered voters in France, 1,004 registered voters in Germany, and 502 voters in Belgium between August 27 and September 16, 2024.

Read More
Ainsley Shea
TAPP Urges Congress Support Patent System, Not Add Legislation

This month, the Senate Committee on Health, Education, Labor and Pensions (HELP) plans to deliberate over two pieces of legislation related to the U.S. Patent system. The bills in question are unnecessary and would cause numerous problems involving both patient safety and drug competition. In the midst of an election year, Congress should be working to make the U.S. patent system stronger, not passing misguided legislation at the 11th hour. 

Read More
Ainsley Shea
Reject Price Control Expansion

In the midst of the Democratic National Convention, the Biden-Harris Administration’s support of prescription drug price control policies has become evident once again. According to the DNC Platform, Democrats want to add “at least” 50 medicines a year to the price-control list, getting to 500 by the end of the decade. This is ridiculous, considering that there are not even 500 branded medicines in existence that qualify for price controls.

Read More
Ainsley Shea
TAPP Applauds No. Carolina State Treasurer Report Exposing 340B Overcharges

North Carolina State Treasurer Dale R. Folwell, CPA, recently released a report finding that 340B hospitals billed state employees an average price markup of 5.4 times their discounted acquisition costs for oncology drugs. Hospitals generated average spread profits as high as $13,617 per claim on cancer drugs paid for by the North Carolina State Health Plan for Teachers and State Employees.

Read More
Ainsley Shea
Stop the Expansion of Drug Price Control Policies

Today, President Joe Biden and U.S. Senator Bernie Sanders teamed up to deliver remarks from the White House regarding their plan supposedly to lower healthcare costs for Americans. Here is the catch: Their plan to lower healthcare costs requires increasing drug price controls across the country, something that would result in dire consequences on patient access, medical innovation, and market competition.

Read More
Ainsley Shea